• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hypertension in 2016: Blood pressure goals, variability and SGLT2 blockade in CKD.

作者信息

Cohen Debbie L, Townsend Raymond R

机构信息

Renal, Electrolyte and Hypertension Division, Perelman School of Medicine at the University of Pennsylvania, 1 Founders Building, 3400 Spruce Street, Philadelphia 19104, USA.

出版信息

Nat Rev Nephrol. 2017 Feb;13(2):75-76. doi: 10.1038/nrneph.2016.189. Epub 2016 Dec 28.

DOI:10.1038/nrneph.2016.189
PMID:28029152
Abstract
摘要

相似文献

1
Hypertension in 2016: Blood pressure goals, variability and SGLT2 blockade in CKD.2016年的高血压：慢性肾脏病中的血压目标、变异性及钠-葡萄糖协同转运蛋白2抑制剂治疗
Nat Rev Nephrol. 2017 Feb;13(2):75-76. doi: 10.1038/nrneph.2016.189. Epub 2016 Dec 28.
2
Sodium-glucose co-transporter 2 inhibitor therapy: use in chronic kidney disease and adjunctive sodium restriction.钠-葡萄糖协同转运蛋白 2 抑制剂治疗：在慢性肾脏病中的应用及辅助钠限制。
Intern Med J. 2022 Oct;52(10):1666-1676. doi: 10.1111/imj.15727. Epub 2022 May 27.
3
Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Across the Spectrum of Hypertension.钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂在各种高血压中的应用。
Am J Hypertens. 2020 Mar 13;33(3):207-213. doi: 10.1093/ajh/hpz157.
4
Recent advances in the management of secondary hypertension: chronic kidney disease.继发性高血压的管理进展：慢性肾脏病
Hypertens Res. 2020 Sep;43(9):869-875. doi: 10.1038/s41440-020-0491-4. Epub 2020 Jun 17.
5
[New aspects of hypertension management in patients with chronic kidney disease].[慢性肾脏病患者高血压管理的新进展]
Rev Med Suisse. 2014 Sep 10;10(441):1668-72.
6
In the Wake of Systolic Blood Pressure Intervention Trial: New Targets for Improving Hypertension Management in Chronic Kidney Disease?继收缩压干预试验之后：改善慢性肾脏病高血压管理的新目标？
Nephron. 2017;135(4):287-290. doi: 10.1159/000455130. Epub 2017 Feb 4.
7
Hypertension Management in Transition: From CKD to ESRD.高血压管理的转变：从慢性肾脏病到终末期肾病
Adv Chronic Kidney Dis. 2016 Jul;23(4):255-61. doi: 10.1053/j.ackd.2016.02.002.
8
Hypertension and chronic kidney disease progression: why the suboptimal outcomes?高血压与慢性肾脏病进展：为何结局不佳？
Am J Med. 2012 Nov;125(11):1057-62. doi: 10.1016/j.amjmed.2012.04.008. Epub 2012 Aug 17.
9
Hypertension control and antihypertensive therapy in patients with chronic kidney disease.慢性肾脏病患者的高血压控制与抗高血压治疗
Am J Hypertens. 2015 Jun;28(6):814-22. doi: 10.1093/ajh/hpu215. Epub 2014 Nov 24.
10
Blood-pressure control and delay in progression of kidney disease in children.儿童的血压控制与肾病进展延缓
N Engl J Med. 2009 Oct 22;361(17):1701-3. doi: 10.1056/NEJMe0908183.

引用本文的文献

1
Emerging horizons: clinical applications and multifaceted benefits of SGLT-2 inhibitors beyond diabetes.新视野：钠-葡萄糖协同转运蛋白2抑制剂在糖尿病之外的临床应用及多方面益处
Front Cardiovasc Med. 2025 Mar 20;12:1482918. doi: 10.3389/fcvm.2025.1482918. eCollection 2025.
2
Blood Pressure Lowering and Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2is): More Than Osmotic Diuresis.降压与钠-葡萄糖共转运蛋白 2 抑制剂（SGLT2is）：不仅仅是渗透性利尿。
Curr Hypertens Rep. 2019 Feb 12;21(2):12. doi: 10.1007/s11906-019-0920-4.

本文引用的文献

1
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.恩格列净与 2 型糖尿病患者的肾脏疾病进展。
N Engl J Med. 2016 Jul 28;375(4):323-34. doi: 10.1056/NEJMoa1515920. Epub 2016 Jun 14.
2
Visit-to-visit variability of blood pressure and death, end-stage renal disease, and cardiovascular events in patients with chronic kidney disease.慢性肾病患者血压的就诊间变异性与死亡、终末期肾病及心血管事件
J Hypertens. 2016 Feb;34(2):244-52. doi: 10.1097/HJH.0000000000000779.
3
Hypertension pharmacogenomics: in search of personalized treatment approaches.
高血压药物基因组学：探寻个性化治疗方法。
Nat Rev Nephrol. 2016 Feb;12(2):110-22. doi: 10.1038/nrneph.2015.176. Epub 2015 Nov 23.
4
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis.强化降压对心血管和肾脏结局的影响：更新的系统评价和荟萃分析。
Lancet. 2016 Jan 30;387(10017):435-43. doi: 10.1016/S0140-6736(15)00805-3. Epub 2015 Nov 7.
5
A Randomized Trial of Intensive versus Standard Blood-Pressure Control.强化与标准血压控制的随机试验
N Engl J Med. 2015 Nov 26;373(22):2103-16. doi: 10.1056/NEJMoa1511939. Epub 2015 Nov 9.
6
Visit-to-visit variability of blood pressure and cardiovascular disease and all-cause mortality: a systematic review and meta-analysis.血压变异性与心血管疾病及全因死亡率的关系：系统评价和荟萃分析。
Hypertension. 2014 Nov;64(5):965-82. doi: 10.1161/HYPERTENSIONAHA.114.03903. Epub 2014 Jul 28.
7
The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).一项比较两种收缩压控制策略的多中心临床试验的设计与原理：收缩压干预试验（SPRINT）
Clin Trials. 2014 Oct;11(5):532-46. doi: 10.1177/1740774514537404. Epub 2014 Jun 5.
8
2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).2014 年成人高血压管理的循证指南：第八届联合国家委员会（JNC 8）任命的专家组报告。
JAMA. 2014 Feb 5;311(5):507-20. doi: 10.1001/jama.2013.284427.
9
Visit-to-visit systolic blood pressure variability and outcomes in hemodialysis.血液透析中逐次就诊的收缩压变异性与预后
J Hum Hypertens. 2014 Jan;28(1):18-24. doi: 10.1038/jhh.2013.49. Epub 2013 Jun 27.
10
Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP).慢性肾脏病患者的血压成分与终末期肾病：肾脏早期评估项目（KEEP）
Arch Intern Med. 2012 Jan 9;172(1):41-7. doi: 10.1001/archinternmed.2011.619.